Please Wait
Applying Filters...
menu
    • menu
    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.

    Virtual Booth

    Contact Supplier

    Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    Menu

    Loncastuximab Tesirine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ADC Therapeutics Completes Phase 3 Enrollment for Zynlonta in Lymphoma
    ADC Therapeutics Completes Phase 3 Enrollment for Zynlonta in Lymphoma

    30 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/adc-therapeutics-announces-completion-of-enrollment-of-phase-3-confirmatory-clinical-trial-of-zynlonta-in-combination-with-rituximab-in-2l-diffuse-large-b-cell-lymphoma-302338974.html

    PR NEWSWIRE
    30 Dec 2024
    Share Share
    ADC touts early Zynlonta results in marginal zone lymphoma
    ADC touts early Zynlonta results in marginal zone lymphoma

    07 May 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/adc-therapeutics-touts-early-zynlonta-results-marginal-zone-lymphoma-raises-105m-through

    FIERCE PHARMA
    07 May 2024
    Share Share
    ADC Reports Q1 2024 Results, Provides Business Update
    ADC Reports Q1 2024 Results, Provides Business Update

    06 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/06/2875646/0/en/ADC-Therapeutics-Reports-First-Quarter-2024-Financial-Results-and-Provides-Business-Updates.html

    GLOBENEWSWIRE
    06 May 2024
    Share Share
    ADC Reports ZYNLONTA® Phase 2 Data In Marginal Zone Lymphoma
    ADC Reports ZYNLONTA® Phase 2 Data In Marginal Zone Lymphoma

    06 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/06/2875641/0/en/ADC-Therapeutics-Announces-Initial-Data-from-Investigator-Initiated-Phase-2-Clinical-Trial-of-ZYNLONTA-in-Patients-with-Relapsed-Refractory-Marginal-Zone-Lymphoma.html

    GLOBENEWSWIRE
    06 May 2024
    Share Share
    Overland ADCT Announces NMPA Accepts BLA & Grants Priority Review for ZYNLONTA
    Overland ADCT Announces NMPA Accepts BLA & Grants Priority Review for ZYNLONTA

    24 Jul 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/07/24/2709420/0/en/Overland-ADCT-BioPharma-Announces-NMPA-Accepts-Biologics-License-Application-and-Grants-Priority-Review-for-ZYNLONTA-for-Treatment-of-Relapsed-or-Refractory-Diffuse-Large-B-cell-Ly.html

    GLOBENEWSWIRE
    24 Jul 2023
    Share Share
    After seven deaths, ADC gets partial hold and decides to stop Zynlonta trial
    After seven deaths, ADC gets partial hold and decides to stop Zynlonta trial

    22 Jul 2023

    // Zoey Becker FIERCE PHARMA

    https://www.fiercepharma.com/pharma/adc-therapeutics-pulls-plug-zynlonta-study-after-fda-partial-hold#:~:text=ADC%20Therapeutics%20pulls%20the%20plug%20on%20Zynlonta%20study%20after%20partial%20FDA%20hold,-By%20Zoey%20Becker&text=A%20week%20after%20ADC%20Therapeutics,an%20FDA%20partial%20clinical%20hold.

    Zoey Becker FIERCE PHARMA
    22 Jul 2023
    Share Share